Du är här


Cantargia AB: Cantargia patent granted in Australia

Cantargia AB ("Cantargia") has obtained a granted patent in Australia
concerning IL1RAP as a target molecule for antibody based therapy and
diagnostic methods of leukemia.

Based on this grant, Cantargia's method for treatment of leukemia has
protection within Europe, South Africa and Australia. The
corresponding application is currently under review by authorities in
e.g. USA, Japan and China.

For further information, please contact
Göran Forsberg, CEO
Telephone: +46 (0)46-275 62 60
E-mail: goran.forsberg@cantargia.com


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.